Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend
Remus Pharmaceuticals Ltd · Outcome · 03 Nov 2026, 9:28 pm
Remus Pharmaceuticals H1 FY27 Consolidated Revenue Up 53% YoY; Declares Interim Dividend Remus Pharmaceuticals posted strong H1 FY27 consolidated financial results, with revenue from operations surging 53.45% YoY to ₹614.12 crore compared to ₹400.20 crore in H1 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 crore, while PAT grew 14.22% YoY to ₹24.66 crore, despite initial setup and operating cost drags from new subsidiaries. The board approved a first interim dividend of ₹1.00 per equity share (face value ₹10) for FY 2026-27, with the record date set for 7th Nov'26.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript · 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet · 29 Oct 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business. · 03 Nov 2026
